In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.
UCB announces European Commission approval of ZILBRYSQ®▼ (zilucoplan) for the treatment of adults with generalized Myasthenia GravisEuropean approval of ZILBRYSQ® (zilucoplan) granted as an add-on to standard therapy for the treatment of generalized Myasthenia Gravis (gMG) in adult patients who are anti-acet.